Sanara MedTech FY Conference Summary Company Overview - **Company Name**: Sanara MedTech (NasdaqCM: SMTI) - **Industry**: Medical Technology focused on surgical wound treatment - **CEO**: Seth Jahn - **CFO**: Elizabeth Taylor - **Market Cap**: $183 million - **Net Revenue (Trailing 12 months)**: Approximately $102 million - **EBITDA Margin**: Approximately $16 million - **Net Income from Continued Operations**: Approximately $1.6 million - **Contracted Facilities**: Over 4,000 across the U.S. [5][27] Core Business and Growth Strategy - **Focus**: Sanara MedTech specializes in innovative products for surgical wound treatment, particularly through its flagship product, CellerateRX, which is designed for use in the operating room (OR) [4][12]. - **Growth Rate**: The company has achieved a 51% compound annual growth rate (CAGR) in net revenue over the past seven years [4]. - **Market Position**: The company aims to target a total addressable market (TAM) of $1 billion with improved clinical outcomes [8]. - **Product Portfolio**: Key products include: - **CellerateRX**: A hydrolyzed surgical powder with a TAM of approximately $3.6 billion in the U.S. [13]. - **BIASURGE**: An antimicrobial wash that is the only no-rinse solution on the market [13]. - **OsStic**: A bioadhesive technology expected to launch in early 2027, which has received Breakthrough Device designation from the FDA [18][29]. Financial Performance and Projections - **2025 Preliminary Results**: Net revenue between $102 million and $103.2 million, representing a 19% increase [26]. - **2026 Revenue Guidance**: Projected net revenue between $116 million and $121 million, indicating a growth of 13% to 17% [27]. - **Cash Position**: $16.6 million at the end of 2025, with long-term debt of approximately $46 million [26]. Sales and Distribution Strategy - **Sales Model**: A hybrid model combining direct sales force and distributor partnerships, with over 400 distributor agreements in place [20][22]. - **Facility Access**: Currently doing business in 1,400 of the 4,000 contracted facilities, with plans to expand into the remaining 2,600 [23][25]. - **Key Drivers for Growth**: Focus on increasing surgeon users, expanding into vascular and plastics specialties, and enhancing education with distributor partners [25]. Research and Development - **Clinical Evidence**: Sanara emphasizes scientific, clinical, and economic evidence for its products, with over 20 published papers supporting CellerateRX [15][19]. - **Product Enhancements**: Ongoing R&D projects aimed at enhancing existing products and preparing for the commercialization of OsStic [29]. Market Positioning and Competitive Strategy - **Pricing Strategy**: Competitive pricing is a key component of the growth strategy, aiming to achieve standard of care through case volume rather than price increases [50]. - **M&A Strategy**: Future acquisitions will focus on complementary products that fit within the company's core offerings, avoiding a broad portfolio of small products [41][46]. Conclusion - Sanara MedTech is positioned for significant growth in the surgical wound treatment market, with a strong focus on innovative products, a solid financial foundation, and a clear strategy for expanding its market presence and product offerings [29].